Despite the progress in secondary prevention, life expectancy after myocardial infarction is poor for some specific groups of patients. High ischemic risk patients could benefit from some strategies of long-term and aggressive antithrombotic therapy provided that their bleeding risk is acceptably low.
Keywords: antiplatelet therapy; acute myocardial infarction; anticoagulant therapy.